On February 11, 2025, Immedica Pharma AB announced the successful completion of the previously announced transaction to acquire all of the outstanding shares of Marinus Pharmaceuticals, Inc. With the completion of the acquisition, Marinus is now a wholly owned subsidiary of Immedica.
To learn more about Immedica and the transaction, please visit the Immedica website.
Mindful Innovation
Mastering Challenges.
Compassion for Patients.
Transforming Medicine.
At Marinus, our passionate team of experts are constantly innovating
with the aim to drastically improve lives affected by seizure disorders.
Ryan, living with CDKL5 deficiency disorder
Commitment
We put people first and uphold the highest standards of integrity as we strive to create a better future for patients, their families, our communities and each other.
Innovation
Grounded in cutting-edge science and research, we empower new ways of thinking to transform lives.
Collaboration
We harness the power of our employees’ diverse perspectives, uniting with healthcare professionals, patient advocacy organizations and families to achieve more together.
Discover the people and stories behind our bold vision.
We are committed to developing treatments for patients with severe, rare forms of epilepsy, implementing a clinical trial and commercial strategy that is guided by our strong scientific rationale, and unlocking new possibilities across a range of seizure disorders.
— Scott Braunstein, M.D., CEO, Marinus
-
Pipeline
Discover the science behind our work
Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings.
-
Focus Areas
Focused on seizure disorders
We are developing breakthrough therapies in status epilepticus, tuberous sclerosis complex, and CDKL5 deficiency disorder.
-
Trials
Our goal is developing safe and effective treatments
We are conducting high quality research in-house, with our scientific advisory board and external consultants to ensure patients are receiving innovative and safe treatment options.
Providing a range of clinical trials to develop innovative treatments for patients
Status Epilepticus
Striving to maintain seizure control
Developing therapies with the potential to provide rapid cessation of status epilepticus and prevent escalation of treatment
Rare Epilepsies
Aspiring to give children significantly less seizures and better quality of life
Developing treatment options with the potential to safely decrease seizure frequency in children with refractory epilepsy
Advocacy & Related Activities
Fostering a community for those impacted by seizure disorders
Collaborating with key groups to support patients and their families, working to lessen the impact of seizure disorders
Want to make an impact?
We are always looking for dedicated and passionate professionals who want to make a positive difference in the lives of those affected by seizure disorders